Zimmer Biomet Holdings Inc (NYSE:ZBH) has been given an average recommendation of “Buy” by the twenty-five brokerages that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, four have given a hold recommendation, seventeen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $141.69.
Several brokerages have issued reports on ZBH. Citigroup dropped their target price on Zimmer Biomet from $132.00 to $121.00 and set a “neutral” rating for the company in a report on Tuesday. Morgan Stanley dropped their target price on Zimmer Biomet from $150.00 to $148.00 and set an “overweight” rating for the company in a report on Monday. BMO Capital Markets restated a “buy” rating and issued a $144.00 target price on shares of Zimmer Biomet in a report on Tuesday, January 30th. Stifel Nicolaus upgraded Zimmer Biomet from a “hold” rating to a “buy” rating and upped their target price for the company from $120.00 to $168.00 in a report on Wednesday, January 31st. Finally, Robert W. Baird restated a “buy” rating on shares of Zimmer Biomet in a report on Wednesday, January 31st.
In other news, VP Chad F. Phipps sold 20,826 shares of the company’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $115.95, for a total value of $2,414,774.70. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Bryan C. Hanson purchased 25,077 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The stock was acquired at an average cost of $119.68 per share, for a total transaction of $3,001,215.36. The disclosure for this purchase can be found here. Corporate insiders own 1.07% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. Bank of Nova Scotia Trust Co. acquired a new position in Zimmer Biomet during the 3rd quarter worth about $112,000. FNY Managed Accounts LLC acquired a new position in Zimmer Biomet during the 3rd quarter worth about $117,000. Cerebellum GP LLC acquired a new position in Zimmer Biomet during the 4th quarter worth about $133,000. We Are One Seven LLC acquired a new position in Zimmer Biomet during the 4th quarter worth about $137,000. Finally, Steward Partners Investment Advisory LLC acquired a new position in Zimmer Biomet during the 3rd quarter worth about $140,000. 88.18% of the stock is currently owned by institutional investors and hedge funds.
Shares of Zimmer Biomet (NYSE:ZBH) traded down $1.74 on Friday, hitting $118.14. The company had a trading volume of 854,944 shares, compared to its average volume of 1,380,000. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.52 and a quick ratio of 0.83. Zimmer Biomet has a 52-week low of $108.03 and a 52-week high of $133.49. The stock has a market capitalization of $23,920.00, a PE ratio of 44.92, a price-to-earnings-growth ratio of 2.09 and a beta of 1.08.
Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.10. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The firm had revenue of $2.07 billion during the quarter, compared to analysts’ expectations of $2.03 billion. During the same period in the previous year, the business earned $2.14 earnings per share. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. sell-side analysts predict that Zimmer Biomet will post 7.82 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Monday, January 29th. Stockholders of record on Friday, December 29th were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.81%. The ex-dividend date was Thursday, December 28th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 36.50%.
COPYRIGHT VIOLATION NOTICE: This report was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.thelincolnianonline.com/2018/03/14/brokerages-set-zimmer-biomet-holdings-inc-zbh-target-price-at-142-38.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.